Halozyme Therapeutics Stock (NASDAQ: HALO) stock price, news, charts, stock research, profile.
Open | $38.710 |
Close | - |
Volume / Avg. | 143.782K / 1.047M |
Day Range | 38.250 - 38.730 |
52 Wk Range | 29.850 - 45.000 |
Market Cap | $4.925B |
P/E Ratio | 18.629 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 8.4% |
Days to Cover | 10.21 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.
Other companies in Halozyme Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by HC Wainwright & Co. on Wednesday, April 17, 2024. The analyst firm set a price target for 50.00 expecting HALO to rise to within 12 months (a possible 29.68% upside). 23 analyst firms have reported ratings in the last year.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $38.555 last updated Today at April 25, 2024 at 12:01 PM EDT.
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.